Tenaya Therapeutics | IPO Presentation Deck

Slide schematic 8/8

diagram 1/1 image 1/1 list 3/3 table 1/1 title 2/2

Components 8

process photo bullet bullet bullet data action-title headline

Tools 1

Problem Statement Canvas slide · 70%

list/bullet: Disease Symptoms and Severity: ~24% of HFpEF population has NYHA Class III or IV disease; list/bullet: Pathophysiology: Poor relaxation and filling of the left ventricle (diastolic dysfunction)

Metrics 0

∅

No metrics

No metric insight is anchored to this slide.

Frameworks 1

causal-chain 90%

The diagram at the bottom illustrates the causal link between cellular pathways, diastolic dysfunction, and HFpEF.

Find anything

Includes a biological mechanism diagram showing how HDAC6 inhibitors target multiple pathways leading to diastolic dysfunction and HFpEF.